Results 241 to 250 of about 65,300 (300)

Delivery of nano‐formulated drugs to solid tumours is selectively increased by co‐application of the vascular disrupting agent CA4P

British Journal of Pharmacology, EarlyView.
Background and purpose Nano‐formulated chemotherapeutics prolong systemic availability of drugs and can reduce systemic toxicity, but their accumulation in solid tumours is often limited and unpredictable. Broadly applicable strategies to selectively enhance tumour delivery are lacking.
Annabel Kitowski, Constanze Heise, Stefanie Sperling, Jasmin Hotz, Danica Bajic, Marina Rubey, Kathrin Klar, Georg Höfner, Julien Vollaire, Veronique Josserand, Jean‐Luc Coll, Oliver Thorn‐Seshold, Petar Marinković, Julia Thorn‐Seshold   +13 more
wiley   +1 more source

Prodrug strategies in developing antiviral nucleoside analogs. [PDF]

RSC Med Chem
Suresh RR, Abuduani T, Kasthuri M, Chen Z, Tber Z, Loubidi M, Zhang H, Zhou L, Zhou S, Li C, Kumari A, Tao S, Wiseman JM, Hurwitz SJ, Amblard F, Schinazi RF.   +15 more
europepmc   +1 more source

[Prodrugs].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2017
openaire   +1 more source

Identification of drug repurposing candidates for the treatment of polycystic kidney disease

British Journal of Pharmacology, EarlyView.
Background and Purpose Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end‐stage renal disease with limited treatment options. Drug repurposing offers a promising strategy to find effective treatments. Experimental Approach We identified birinapant, bardoxolone methyl and salicylic acid as repurposing candidates for ADPKD and
Alina Meyer, Paraskevi Sotiropoulou, Koussai Bouker, Dennis Svedberg, Rebekkah Hammar, Hester Bange, Per Larsson, André Mateus, Daniel R. Dietrich, Per Artursson   +9 more
wiley   +1 more source

Bis-prodrug cryopreserved lipid nanoparticles with enzymatically triggered release. [PDF]

Nanoscale Adv
Hogarth C, Arnold K, Elkateb H, Rannard S, McDonald TO.   +4 more
europepmc   +1 more source

The nitty‐gritty of vascular permeability in cancer: targeting blood endothelium to control metastases

British Journal of Pharmacology, EarlyView.
Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher, Mérone Da Costa Oliveira, Adrien Levesque, Alexandre Rutault, Patrick Savoyaud, Nicolas Bréchot, Stéphane Germain   +6 more
wiley   +1 more source

Anti-Cancer Research Progress of Triptolide: Mechanisms of Action, Structural Modifications, Nanodelivery Systems and Clinical Challenges. [PDF]

Drug Des Devel Ther
Li ZX, Zang L, Li YQ, Zhang M, Zhao DM, Han XY, Zhao JF, Ding CH, Liu WS.   +8 more
europepmc   +1 more source

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source

Controlled Self-Immolative Release of β-Lapachone via an Optimized <i>para</i>-Hydroxybenzyl Linker for Targeted Pancreatic Cancer Therapy. [PDF]

J Am Chem Soc
Becher JB, Dutta N, Navo CD, Dunsmore L, Misteli R, Gil de Montes E, Simpson GG, Alewine CC, Jiménez-Osés G, Bernardes GJL.   +9 more
europepmc   +1 more source

Exploiting Methyl Triazenes as Attractive Alternatives to Temozolomide and Dacarbazine for Cancer Therapy. [PDF]

Molecules
Ribeiro Morais G, Nwokolo GC, Lamptey Mills HNL, Wheelhouse RT, Falconer RA.   +4 more
europepmc   +1 more source